The UC Davis Cancer Center is a matrix organization under the aegis of the UC Davis Health System integrating the UC Davis School of Medicine and the UC Davis Medical Center, and the University of California, Davis. Located on the campus of the UC Davis Medical Center in Sacramento, California, its administrative clinical and research facilities are under the leadership of the Director and Principal Investigator of this P30 application. The Cancer Center draws its 209 members from the faculty of UC Davis and investigators at the Lawrence Livermore National Laboratory (LLNL), the USDA Western Human Nutrition Research Center and the California Department of Public Health. Peer-reviewed funding for UC Davis totals $30, 997, 409 of which $6,615,009 is provided by the NCI. Peer-reviewed funded research projects of the LLNL members totals $9, 467, 454, of which $2,499,000 is provided by the NCI. Investigations at the other organizations contributing members are provided research funding through the US Department of Agriculture and the State of California respectively. At the UC Davis Cancer Center, research is organized into si programs: (1) Molecular Oncology, (2) Cancer Biology in Animals, (3) Cancer Therapeutics, (4) Cancer Etiology, Prevention, and Control, (5) Prostate Cancer, and (6) Biomedical Technology. This first time, competitive application for a P30 [Cancer Center Support Grant] proposes support for (1) senior leadership, (2) program leadership, (3) developmental programs, (4) administration, (5) planning and evaluation activities, (6) shared resources including molecular pathology, optical pathology, optical biology, mouse biology, the clinical trials support unit, biostatistics/bioinformatics, and pharmacokinetics, (7) the Protocol Review and Monitoring System, and (8) protocol-specific research.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA093373-03
Application #
6760058
Study Section
Subcommittee G - Education (NCI)
Program Officer
Marino, Michael A
Project Start
2002-07-01
Project End
2005-06-30
Budget Start
2004-07-23
Budget End
2005-06-30
Support Year
3
Fiscal Year
2004
Total Cost
$1,334,400
Indirect Cost
Name
University of California Davis
Department
Urology
Type
Schools of Medicine
DUNS #
047120084
City
Davis
State
CA
Country
United States
Zip Code
95618
Braithwaite, Dejana; Miglioretti, Diana L; Zhu, Weiwei et al. (2018) Family History and Breast Cancer Risk Among Older Women in the Breast Cancer Surveillance Consortium Cohort. JAMA Intern Med 178:494-501
Unger, Jakob; Sun, Tianchen; Chen, Yi-Ling et al. (2018) Method for accurate registration of tissue autofluorescence imaging data with corresponding histology: a means for enhanced tumor margin assessment. J Biomed Opt 23:1-11
Wang, Guobao; Corwin, Michael T; Olson, Kristin A et al. (2018) Dynamic PET of human liver inflammation: impact of kinetic modeling with optimization-derived dual-blood input function. Phys Med Biol 63:155004
Winer, Rachel L; Tiro, Jasmin A; Miglioretti, Diana L et al. (2018) Rationale and design of the HOME trial: A pragmatic randomized controlled trial of home-based human papillomavirus (HPV) self-sampling for increasing cervical cancer screening uptake and effectiveness in a U.S. healthcare system. Contemp Clin Trials 64:77-87
Withers, Sita S; Skorupski, Katherine A; York, Daniel et al. (2018) Association of macrophage and lymphocyte infiltration with outcome in canine osteosarcoma. Vet Comp Oncol :
Floc'h, Nicolas; Martin, Matthew J; Riess, Jonathan W et al. (2018) Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 Insertions. Mol Cancer Ther 17:885-896
Shih, Tsung-Chieh; Liu, Ruiwu; Wu, Chun-Te et al. (2018) Targeting Galectin-1 Impairs Castration-Resistant Prostate Cancer Progression and Invasion. Clin Cancer Res 24:4319-4331
Weiss, Robert H (2018) Metabolomics and Metabolic Reprogramming in Kidney Cancer. Semin Nephrol 38:175-182
Hegde, John V; Shaverdian, Narek; Daly, Megan E et al. (2018) Patient-reported quality-of-life outcomes after de-escalated chemoradiation for human papillomavirus-positive oropharyngeal carcinoma: Findings from a phase 2 trial. Cancer 124:521-529
Arun, Adith S; Tepper, Clifford G; Lam, Kit S (2018) Identification of integrin drug targets for 17 solid tumor types. Oncotarget 9:30146-30162

Showing the most recent 10 out of 836 publications